A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to Methotrexate Therapy.

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to Methotrexate Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Genmab; GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 May 2011 Actual initiation date (January 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top